Telaprevir to boceprevir switch highlights lack of cross-reactivity

Clin Infect Dis. 2013 Feb;56(4):552-4. doi: 10.1093/cid/cis960. Epub 2012 Nov 19.

Abstract

Hepatitis C viral protease inhibitors increase sustained virologic response rates compared to interferon and ribavirin but also add side effects. Telaprevir and boceprevir are structurally similar, and share cross-resistant mutations. This case report highlights successful management of telaprevir skin rash and anal discomfort by switching to boceprevir.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antiviral Agents* / adverse effects
  • Antiviral Agents* / therapeutic use
  • Cross Reactions
  • Drug Substitution
  • Eosinophilia / chemically induced*
  • Exanthema / chemically induced*
  • Genotype
  • Hepacivirus / drug effects
  • Hepacivirus / physiology
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Oligopeptides / adverse effects*
  • Proline / analogs & derivatives*
  • Proline / therapeutic use
  • RNA, Viral / genetics
  • Viral Load

Substances

  • Antiviral Agents
  • Oligopeptides
  • RNA, Viral
  • telaprevir
  • N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
  • Proline